arrow
R

Regina Barragán-Carrillo

instituto nacional de cancerologia
H指数:11
被引数:515

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Independent cancer research in low- and middle-income countries: why it matters and how to build it

低收入和中等收入国家的独立癌症研究:为何重要及如何构建

2026-09-070
OAAI
Disparities in Outcomes in Latino Subpopulations with Localized Prostate Cancer Undergoing Radical Prostatectomy: A Population-Based Analysis

局部前列腺癌行根治性前列腺切除术的拉丁裔亚人群结局差异:一项基于人群的分析

Cancers
IF4.4
2026-04-030
OAAI
Clinical Predictors and Prognostic Significance of Pathologic Disease Upstaging at Radical Cystectomy in Patients with Muscle-Invasive Bladder Cancer

肌层浸润性膀胱癌患者根治性膀胱切除术中病理疾病升级的临床预测因素及预后意义

2025-10-090
OA
Efficacy and safety of antibody-drug conjugate combination therapy in advanced urothelial carcinoma

抗体药物偶联物联合疗法在晚期尿路上皮癌中的疗效与安全性

2025-10-070
OAAI
VHL and TP53 mutation status are not associated with response or progression-free survival in metastatic renal cell carcinoma treated with VEGF-targeted therapies

VHL和TP53突变状态与接受VEGF靶向治疗的转移性肾细胞癌的治疗反应或无进展生存期无关。

2025-10-010
OAAI
Evaluating global disparities in clinical trial availability for renal cell carcinoma

评估肾细胞癌临床试验可及性的全球差异

2025-10-010
OAAI
Characterization of aberrant alternative splicing landscape in patients with metastatic renal cell carcinoma

转移性肾细胞癌患者中异常替代剪接景观的特征分析

2025-10-010
OAAI
Real-World evidence shows no survival advantage with contemporary first-line strategies in papillary renal cell carcinoma: a call for randomized trials

真实世界证据表明,在乳头状肾细胞癌中,当代一线策略并未显示出生存优势:呼吁开展随机试验

2025-10-010
OA
Clinical and Pathological Predictors for Occult Lymph Node Involvement in Patients With Clinical Node-Negative Bladder Cancer Undergoing Radical Cystectomy

临床和病理学预测因子:在接受根治性膀胱切除术的临床淋巴结阴性的膀胱癌患者中 occult 淋巴结受累的预测因子

2025-09-010
PRE
Impact of Latino ethnicity on the gut microbiome and response to immune checkpoint inhibition (ICI) with CBM588 in patients (pts) with metastatic renal cell cancer (mRCC)

拉美裔族裔对肠道微生物组和接受CBM588治疗的免疫检查点抑制剂(ICI)反应的影响,在转移性肾细胞癌(mRCC)患者(pts)中的研究

2024-09-010
PRE
Real-world (RW) characteristics and outcomes in patients (pts) with muscle-invasive urothelial carcinoma (MIUC) treated with adjuvant nivolumab (NIVO) with or without neoadjuvant chemotherapy (NAC)

真实世界(RW)中接受辅助纳武利尤单抗(NIVO)治疗,联合或不联合新辅助化疗(NAC)的肌肉浸润性尿路上皮癌(MIUC)患者的特征与结局

2024-09-010
PRE
Multicenter analysis of first-line (1L) regimens (BEP vs VIP) in patients (pts) with non-seminomatous germ cell tumors (NSGCTs) who subsequently underwent high-dose chemotherapy (HDCT)

多中心分析非精原细胞瘤生殖细胞肿瘤(NSGCTs)患者(pts)接受大剂量化疗(HDCT)后的一线(1L)方案(BEP vs VIP)的比较。

2024-09-010
PRE
Impact of Synchronous versus Metachronous Metastasis on Outcomes in Patients with Metastatic Renal Cell Carcinoma Treated with First-line Immune Checkpoint Inhibitor-based Combinations
2024-09-010
OAAI
Cabozantinib and nivolumab with or without live bacterial supplementation in metastatic renal cell carcinoma: a randomized phase 1 trial

卡博替尼和nivolumab联合或不联合活细菌补充治疗转移性肾细胞癌: 一项随机1期试验

2024-06-285
OAAI
Prevalence of Dietary Modification and Supplement Use in Patients with Metastatic Renal Cell Carcinoma Receiving Systemic Therapy
2024-05-260
OAAI